Urinary Incontinence in Multiple Sclerosis — Free SCA Practice Case
Urinary Incontinence in Multiple Sclerosis
Station Timer
Golden Minute
Initial Introduction
•Introduce yourself
•Ask an open question — "How can I help you today?"
•Listen — don't interrupt
•Catch early cues
Data Gathering
History, ICE & Diagnosis
Clinical Management
Diagnosis, Plan & Decisions
Safety Net
Follow-up & Close
Materials for Candidate
Please review before starting the consultation
Full Name
Jessica Hayes
Age
32 years
Consultation Type
VideoAge
32 (DOB: 15/09/1993)
Situation
Telephone or Video Consultation.
Reason for Encounter
"Patient booked a routine appointment. Triage note simply states: 'MS getting worse. Having bladder issues.'"
Medical Records
- ●PMH: Relapsing-Remitting Multiple Sclerosis (RRMS) - diagnosed age 27. Last relapse was 2 years ago (optic neuritis).
- ●Medications: Dimethyl Fumarate (Tecfidera) 240mg BD.
- ●Allergies: NKDA.
Recent Notes
- ●Annual MS review 6 months ago: Neurology noted stable disease. EDSS (Expanded Disability Status Scale) score very low. Fully mobile.
Patient Script
For the friend playing the patient role
Character Overview: You are Jessica, a 32-year-old marketing executive. You are fiercely independent and usually manage your MS very well. However, over the last two weeks, your bladder has completely betrayed you. You have developed intense, sudden urges to urinate and have wet yourself on the way to the bathroom three times, including once at the office. You are utterly humiliated. You are wearing thick sanitary pads to work and have stopped drinking water during the day to try and prevent accidents. You are also terrified. You believe this sudden loss of bladder control means your MS is transitioning into the "Secondary Progressive" phase, and you are having nightmares about ending up in a wheelchair or needing a permanent catheter. You feel a bit run-down and your urine has been smelling quite strong recently, but you assume that is just because you are deliberately dehydrating yourself. You will not volunteer the strong-smelling urine, your fluid restriction, or your terror of becoming wheelchair-bound unless the doctor specifically audits your fluid intake, screens for an infection, or asks about your underlying fears.
Consultation Flow & Responses:
- ●
The Opening:
- ●
If the doctor asks an open question: "Hi Doctor. This is really hard for me to talk about. My MS is definitely getting worse. For the last couple of weeks, my bladder is completely out of control. When I need to go, I have zero warning. I had an... accident at work on Tuesday. I just need to know what the next steps are."
- ●
Data Gathering (The Layers):
- ●
Layer 1: Bladder Diary (OAB vs. Overflow):
- ●
If asked to describe the symptoms: "It's an intense, sudden urge. I literally have seconds to find a toilet. I'm going maybe 12 times a day."
- ●
If asked if she feels she empties completely: "I think so. It's just that it fills up again so quickly."
- ●
Layer 2: The UTI Screen (The Hidden Trigger):
- ●
If asked about pain, burning, or smell (Dysuria/Hematuria): "It doesn't burn when I pee, but I do feel a bit shivery sometimes. And yes, my urine is quite dark and smells quite strong, but I just thought that was because I've stopped drinking water."
- ●
If asked WHY she stopped drinking water: "Because I'm terrified of wetting myself at work! I only have a few sips of coffee all day."
- ●
Layer 3: The Red Flag Screen (Cauda Equina / Cord Compression):
- ●
If asked about bowel control or numbness between her legs: "No, my bowels are totally normal. No numbness down there. My legs feel a bit heavier than usual, but nothing major."
- ●
Layer 4: Exploring ICE (The Core Fear):
- ●
If the doctor asks what she is most worried about: Reaction (The Reveal): You sound incredibly vulnerable. "I'm 32 years old and I'm wearing incontinence pads to business meetings. But mostly... I'm terrified this is it. Does this mean my MS is becoming progressive? Am I going to need a catheter permanently?"
ICE — Ideas, Concerns, Expectations
(Actor guidance — the patient does not raise these unprompted. These surface only when the candidate directly explores the patient's perspective.)
- ●
Ideas: Jessica believes her bladder problems are caused by her MS getting worse. She has read about Secondary Progressive MS online and has convinced herself that the sudden onset of urinary incontinence means she is transitioning into this phase. It has not occurred to her that a simple urinary tract infection could be mimicking or triggering her symptoms — she does not associate UTIs with the typical burning sensation she has not experienced.
- ●
Concerns: Her deepest fear is disability and loss of independence. She is terrified of ending up in a wheelchair or needing a permanent catheter. Beyond the long-term fear, she is also acutely humiliated by the incontinence — she is a senior professional who presents to clients, and the idea that colleagues might notice she is wearing pads is mortifying. She is also worried that her deliberate fluid restriction might be making things worse but feels trapped because drinking more feels like it will cause more accidents.
- ●
Expectations: She wants a clear answer about whether this means her MS is progressing. She is hoping the doctor will either reassure her or be honest with her. She also wants a practical plan to stop the incontinence — she cannot keep going to work like this. If there is a simple explanation and treatment, she will be hugely relieved, but she needs to understand why this is happening before she can accept any plan.
If Asked — Medical History and Medications
(Actor guidance — the patient responds naturally to direct questions about her medical history and medications.)
- ●
If asked about her MS diagnosis: "I was diagnosed when I was 27. I had numbness down one side and some problems with my balance — they did an MRI and found the lesions. It was a huge shock at the time, but honestly I've been pretty well since."
- ●
If asked about previous relapses: "I've only had one proper relapse since the diagnosis — about two years ago I lost the vision in my right eye for a few weeks. Optic neuritis, they called it. It was terrifying but it came back fully. Touch wood, nothing since then."
- ●
If asked about her Tecfidera (Dimethyl Fumarate): "I take the Tecfidera twice a day — 240mg morning and evening. I've been on it for a few years now. It gave me awful stomach cramps and flushing when I first started, but that settled down. I'm pretty good at remembering to take it. I haven't missed any doses recently."
- ●
If asked about side effects from Tecfidera: "The main thing was the stomach problems at the start — really bad cramps and feeling sick after taking it. And my face would go bright red and hot. But that's all settled now. I haven't noticed anything new."
- ●
If asked about her last neurology review: "I saw the neurologist about six months ago. They said everything looked stable — my score was really low, which is good apparently. They were really pleased with how I was doing."
- ●
If asked about allergies: "No, no allergies to anything."
Social History and Lifestyle Impact
(Actor guidance — volunteered naturally in conversation when relevant, not delivered as a monologue.)
- ●
Occupation and daily life: Jessica works as a marketing executive at a mid-sized agency. Her role involves client presentations, team meetings, and occasional travel. She is ambitious and has just been put forward for a senior account director role. Her work environment is open-plan with shared bathrooms on a different floor.
- ●
Lifestyle impact of the condition: "I had to present to a new client last Thursday and I spent the whole meeting clenching, barely listening to what they were saying. I couldn't concentrate at all — I was just thinking about whether I could make it to the toilets in time. The bathrooms are on a different floor from our office, so if I get the urge, I have to walk past everyone. I actually left in the middle of a meeting on Monday and my manager asked if I was okay. I just said I felt sick." "I've cancelled drinks with friends twice this week because I'm scared of being out somewhere without a toilet nearby. I used to go running three times a week but I haven't been since this started — I'm too frightened. I feel like my whole life is shrinking around this."
If Asked — Associated Symptoms
(Actor guidance — the patient responds to direct questions. Both positives and negatives should sound natural.)
- ●
If asked about fever or temperature: "I haven't taken my temperature, but I've been feeling a bit shivery and run-down for the past week or so. I just put it down to being stressed and not drinking enough."
- ●
If asked about back pain or loin pain: "No, no pain in my back or sides. Nothing like that."
- ●
If asked about blood in the urine: "No, I haven't noticed any blood. It's just very dark and strong-smelling."
- ●
If asked about vaginal discharge: "No, nothing unusual down there — no discharge or itching."
- ●
If asked about nocturia (getting up at night): "Yes, actually — I'm getting up three or four times a night now, which is completely new for me. I used to sleep right through."
- ●
If asked about visual symptoms or changes in vision: "No, my eyes are fine. Nothing like the optic neuritis I had before."
- ●
If asked about new weakness in arms or legs: "My legs have felt a bit heavy and tired, but honestly I think that's just because I'm exhausted from not sleeping. I haven't noticed any actual weakness — I can still walk and do everything normally."
- ●
If asked about new numbness or tingling: "No new tingling or pins and needles anywhere. Nothing like when I was first diagnosed."
- ●
If asked about balance or coordination problems: "No, my balance is fine. I'm not stumbling or falling."
- ●
If asked about cognitive symptoms (memory, concentration): "I've been finding it hard to concentrate at work, but I think that's because I'm constantly anxious about my bladder, not because of my brain. I'm not forgetting things."
- ●
If asked about swallowing difficulties: "No, swallowing is fine."
- ●
If asked about fatigue: "I'm definitely more tired than usual, but I'm barely sleeping because of getting up to pee all night, and I'm not drinking enough water during the day. So I think that explains it."
- ●
If asked about sexual function: "I haven't really noticed any changes there. Things are fine with my partner."
- ●
If asked about recent illness or infections: "Nothing specific — just feeling generally a bit run-down and shivery for the past week or so."
- ●
If asked about stress or mental health: "I mean, this whole thing is making me really anxious. I'm not sleeping, I'm dreading going to work, and I keep googling 'secondary progressive MS' which I know I shouldn't. But I wasn't anxious or low before this started — this is all because of the bladder."
Negotiation & Collaborative Management Plan:
- ●
If the Doctor immediately diagnoses MS progression and prescribes bladder medication (e.g., Oxybutynin):
- ●
Reaction: "Okay. So my MS is definitely getting worse then? I'll take the pills." (Candidate critically fails for diagnosing progression without ruling out a UTI, and prescribing antimuscarinics without a bladder scan).
- ●
If the Doctor recognizes the likelihood of a UTI / Pseudo-relapse:
- ●
Reaction: "A urine infection? But it doesn't sting like a normal UTI. Are you saying a simple infection can make my MS act up like this?"
- ●
If the Doctor addresses the fluid restriction:
- ●
Reaction: "I know it sounds silly to stop drinking water, but I was just so desperate to not have an accident. If I drink more, won't I just leak more?"
- ●
If the Doctor explains the plan (Urine dip, Bladder scan, then treatment):
- ●
Reaction: "That makes a lot of sense. So we rule out an infection today, check if I'm emptying my bladder properly, and if it's clear, the MS nurses can help me with medication? I feel so much better knowing there's a process."
Mark Scheme
Domain 1: Data Gathering and Diagnosis
Domain 2: Clinical Management and Medical Complexity
Domain 3: Relating to Others
Clinical Learning Points
The "Pseudo-Relapse" in Demyelinating Disease
This is a highly testable concept in the SCA and a critical safety principle in managing any patient with MS.
- ●A true MS relapse involves new, active demyelination in the CNS, developing over days to weeks. Symptoms are genuinely new or represent progression in a previously unaffected area.
- ●A pseudo-relapse is a transient worsening — or unmasking — of previously established MS symptoms, triggered by a physiological stressor. The commonest triggers are: systemic infection (UTI is the most frequent), fever, heat (Uhthoff's phenomenon), metabolic disturbance, and severe physical or psychological stress.
- ●The mechanism: Systemic inflammation and raised body temperature impair electrical conduction through already-demyelinated, structurally vulnerable nerve pathways — symptoms emerge without any new CNS lesion.
- ●The clinical rule: You must never diagnose a true MS relapse, nor initiate high-dose corticosteroids, without first rigorously excluding an underlying infective or metabolic trigger. Treating the UTI typically resolves the neurological flare completely within days.
- ●A two-week onset of urgency in a patient with previously stable RRMS is a pseudo-relapse pattern until proven otherwise. The insidious, progressive functional decline of Secondary Progressive MS (SPMS) does not present acutely over a fortnight.
Neurogenic Bladder in MS: Storage vs. Emptying
MS can affect the bladder in two distinct and mechanistically opposite ways. The GP must understand the difference — getting it wrong causes direct patient harm.
- ●Storage failure — Detrusor Overactivity (DO): Spinal cord lesions disrupt descending inhibitory signals from the brain. The detrusor becomes hyper-reflexic, contracting at low bladder volumes. Symptoms: urgency, high frequency, urge incontinence, nocturia. This is the most common neurogenic bladder pattern in MS.
- ●Emptying failure — Detrusor-Sphincter Dyssynergia (DSD): The detrusor contracts to void, but the external urethral sphincter simultaneously contracts rather than relaxing. The result is functional outflow obstruction, a chronically distended bladder, and eventually overflow incontinence — which can present identically to urge incontinence on history alone.
- ●These two conditions require opposite management. Distinguishing them requires a post-void residual (PVR) ultrasound, not history alone.
- ●On history, clarify the incontinence phenotype: urge incontinence features urgency with a short warning, high frequency, and large-volume leaks. Overflow features constant dribbling, poor stream, and a sense of incomplete emptying. Stress incontinence follows exertion or coughing and has no urgency. In MS, history alone cannot safely distinguish DO from DSD — the PVR scan is mandatory before treatment.
UTI Management in Women: Guideline-Consistent Prescribing
When a UTI is identified as the likely pseudo-relapse trigger, treat it correctly per NICE CKS guidance for lower UTI in women.
- ●First-line: Nitrofurantoin 100mg modified-release twice daily for 3 days (if eGFR ≥30 ml/min/1.73m²).
- ●Alternative first-line: Trimethoprim 200mg twice daily for 3 days (if local resistance rates are acceptable and the patient has not recently received trimethoprim).
- ●Send a mid-stream urine (MSU) for culture before or alongside starting empirical treatment — this allows de-escalation or targeted therapy if the initial choice is inappropriate.
- ●In a patient with MS, do not withhold antibiotic treatment pending culture results when there is a clinical diagnosis of UTI: the risk of a prolonged pseudo-relapse from untreated infection outweighs the risk of empirical prescribing with a correct first-line agent.
- ●Resolution of bladder symptoms following antibiotic treatment strongly supports the pseudo-relapse diagnosis. Persistent symptoms after treatment completion warrant further investigation.
- ●UTI in MS may present atypically. Classical dysuria may be absent due to neurogenic sensory changes. A high index of suspicion is warranted when any MS patient presents with an acute symptomatic worsening, even without the burning discomfort expected in a neurologically intact patient.
The Pharmacological Trap: Why You Must Bladder Scan First
This is the most important patient safety point in this case.
- ●The danger: If a GP hears "urgency and frequency" and prescribes an antimuscarinic (oxybutynin, tolterodine, solifenacin) without first confirming bladder emptying, they risk causing acute, painful urinary retention in a patient who has DSD rather than isolated DO.
- ●The mandatory step: Before initiating any pharmacological treatment for OAB in a patient with a neurological condition, perform a Post-Void Residual (PVR) ultrasound bladder scan. A PVR of >100 ml is generally considered significant.
- ●If PVR is elevated, antimuscarinics are contraindicated. The patient requires specialist assessment and may need Intermittent Self-Catheterisation (ISC) to manage retention safely.
- ●This applies regardless of symptom pattern: you cannot exclude DSD on symptoms alone.
First-Line Non-Pharmacological Management: Fluid and Dietary Advice
These interventions are often omitted but are supported by NICE CKS as mandatory first-line treatment for OAB — and are directly relevant to the physiology of this case.
- ●Increase fluid intake to 1.5–2 litres of water per day. Restricting fluids concentrates urine, raising its acidity and osmolality. Concentrated urine is a direct chemical irritant to the urothelium and a potent trigger for detrusor overactivity. Fluid restriction paradoxically worsens urgency.
- ●Reduce or eliminate caffeine. Coffee, tea, and energy drinks are recognised bladder irritants that lower the sensory threshold for urgency. Caffeine also has a mild diuretic effect. Both mechanisms worsen OAB.
- ●Bladder training — gradually extending the interval between voids — is a first-line behavioural intervention for OAB and should be introduced or arranged via the MS continence nurse if the UTI is excluded.
- ●The explanation of why fluid restriction worsens rather than improves urgency is essential to patient adherence: this feels counterintuitive to patients and they will not follow the advice without understanding the mechanism.
Drug Selection in Neurogenic OAB (Exam Gold)
If the PVR is safe and pharmacological treatment is indicated after specialist assessment:
- ●Avoid oxybutynin in MS patients. Oxybutynin crosses the blood-brain barrier and carries a high systemic anticholinergic burden. In patients who already experience cognitive fatigue and processing difficulties, it can cause significant worsening of cognition, confusion, and mood.
- ●Mirabegron (a beta-3 adrenoceptor agonist) relaxes the detrusor without anticholinergic effects. It is the preferred first-line agent for neurogenic OAB in MS — typically initiated by the specialist team after urodynamic assessment.
- ●Trospium is an antimuscarinic that does not cross the blood-brain barrier and is therefore a safer option than oxybutynin if an antimuscarinic is preferred.
- ●Intradetrusor botulinum toxin A is a highly effective second-line intervention for refractory neurogenic detrusor overactivity in MS, administered by urology or neurology. It is worth mentioning to the patient as a further option if first-line treatment fails.
- ●In a first GP appointment, do not commit to a specific bladder medication. The correct management is: treat the UTI, arrange PVR scan, refer to the MS nurse or continence service for ongoing assessment and drug initiation.
Common Candidate Mistakes in This Station
These are the errors most likely to separate a pass from a fail in this specific case.
- ●Diagnosing SPMS on a two-week history. Secondary progressive MS is defined by a gradual, sustained accumulation of disability over at least six months, independent of relapses. A two-week acute onset of urgency does not meet that definition clinically or diagnostically.
- ●Prescribing antimuscarinics without a bladder scan. The single most dangerous management error. Always obtain a PVR result before initiating any OAB pharmacotherapy in a neurological patient.
- ●Missing the UTI because there is no dysuria. Neurogenic sensory change is common in MS. The absence of burning on micturition does not exclude infection. Screen systematically: colour, odour, systemic features (shivers, malaise, nocturia).
- ●Failing to address the fluid restriction. The patient's self-imposed dehydration is maintaining and worsening her symptoms. Identifying it and explaining the paradox is both a Domain 1 data-gathering indicator and a Domain 2 management point.
- ●Ignoring the occupational context. This patient has a promotion in progress and client-facing responsibilities. Acknowledging the professional stakes and framing the management plan around her functional goals is essential for a clear pass in Domain 3.
- ●Closing without safety-netting for treatment failure. If the UTI resolves but bladder symptoms persist, the patient needs a clear instruction to re-contact the surgery — not a generic "come back if worried."
Safety-Netting and Follow-Up
- ●Review after antibiotic course: Arrange a telephone review once the MSU culture result is available and after the antibiotic course is completed to confirm symptom resolution.
- ●If symptoms persist after treating the UTI: Refer urgently to the MS nurse or neurology team for urodynamic assessment. Persistent neurogenic bladder dysfunction requires specialist management.
- ●Red flags requiring urgent reassessment: New bowel incontinence, saddle anaesthesia, bilateral leg weakness, or sudden severe urinary retention — these are signs of acute spinal cord compression or severe spinal relapse and require emergency neurology review (999 or emergency department).
- ●Signs of a true MS relapse: New neurological symptoms in a different anatomical territory, or failure to return to baseline after treating the infection, should prompt urgent neurology contact via the MS team.
- ●Discourage "googling" SPMS: Advise the patient to direct questions about disease trajectory to her neurology team at her next scheduled review, rather than self-researching, as online information is frequently non-specific and anxiety-provoking.